J&J wins full ap­proval for blad­der can­cer drug

The FDA on Fri­day con­vert­ed its ac­cel­er­at­ed ap­proval of John­son & John­son’s blad­der can­cer drug Balver­sa to a full ap­proval.

Balver­sa, al­so known as erdafi­tinib …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER